From Wiktionary, the free dictionary
Jump to navigation Jump to search
See also: mab, MAb, Mab, mAb, and måb






  1. (pharmacology) monoclonal antibody

Usage notes[edit]

USAN guidelines for non-proprietary names of monoclonal antibodies are as follows:

  • an arbitrary prefix to create a unique name (officially monosyllabic)
  • a suffix for the disease state
  • a suffix for the animal source
  • -mab to identify it as a monoclonal antibody (MAb)

The source suffixes are as follows:

-a- for rat-derived,
-e- for hamster,
-i- for primate,
-o- for mouse,
-u- for human,
-xi- for chimeric,
-zu- for humanized,
-xizu- for humanized and chimeric,
-axo- for rat-mouse hybrid.

The disease target suffixes are:

-vir- viral,
-bac- bacterial,
-lim- immune system, immunomodulator,
-les- infectious lesions,
-cir- cardiovascular
-col- colon tumor,
-mel- melanoma,
-mar- mammary tumor,
-got- testicular (gonad) tumor,
-gov- ovarian (gonad) tumor,
-pro- prostate tumor,
-tum- other tumors, or combinations of the above;
-ner- nervous system,
-kin- interleukin,
-mul- musculoskeletal,
-os- bone,
-toxa- toxin,
-fung- fungus

Other attested target affixes are -anibi- and -neur-. The target affix takes the primary stress.

For instance, capromab is a murine MAb that targets prostate cancer; imiciromab pentatate is used to target myocardial infarctions; satumomab pendetide is used for both colorectal and ovarian cancers.

For humanized (-zu-) and chimeric (-xi-) MAbs (and -xizu-), the final consonant of the target suffix is dropped, and for all others the o of -pro- and the a of -toxa- is dropped: natalizumab, a humanized monoclonal antibody used in the treatment of multiple sclerosis (an immunological disease).

Derived terms[edit]

Related terms[edit]